Get started
Author

Anna de Daniel

Observed names: Anna De Daniel, Anna de Daniel i Bisbe
ORCID: 0009-0007-7568-2527
Observed ORCID: 0009-0007-7568-2527
OpenAlex ID: A5071259995
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
2024 · Anna de Daniel, Luis Gerardo Rodríguez‐Lobato, et al. · HemaSphere · 14
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
2025 · Luis Gerardo Rodríguez-Lobato, Anna de Daniel, et al. · Blood Cancer Journal · 11
PDF
Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma
2022 · Luis Gerardo Rodríguez-Lobato, Anna de Daniel i Bisbe, et al. · Blood · 6
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al. · Cancer Immunology Research · 4
Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution
2023 · Luis Gerardo Rodríguez-Lobato, Natalia Tovar, et al. · Cancers · 3
PDF
Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P
2025 · David F. Moreno, Ferran Nadeu, et al. · Frontiers in Immunology · 2
PDF
Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes
2026 · Luis Gerardo Rodríguez-Lobato, Anna de Daniel, et al. · Bone Marrow Transplantation · 1
PDF
Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
2022 · Luis Gerardo Rodríguez-Lobato, Oriol Cardus, et al. · Blood · 1
Clonotypic characterization defines B‐cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies
2026 · David F. Moreno, Ferran Nadeu, et al. · HemaSphere
Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain
2026 · Oriol Cardus, Joan Mañé Pujol, et al. · Journal for ImmunoTherapy of Cancer
PDF
The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data
2025 · Aina Oliver-Caldes, Natalia Tovar, et al. · Blood
PDF
Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 9 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 8 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 7 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
2025 · Luis Gerardo Rodríguez-Lobato, Oriol Cardús, et al.
PDF
Works count: 29
Citation count: 41
H-index: 4
I10-index: 2
Year
Topic
Type